Syntis Bio, a Boston-based company, is now reportedly developing an innovative daily pill aimed at mimicking the effects of gastric bypass surgery as a weight loss solution.
This experimental drug creates a temporary coating in the small intestine, potentially offering an alternative to traditional bariatric surgery and GLP-1 medications like Ozempic.
Recent data shared at the European Congress on Obesity and Weight Management suggests that the drug is safe and may effectively suppress hunger.
Currently, approximately 12% of Americans have tried GLP-1 drugs, but many discontinue their use due to side effects like nausea and the inconvenience of injections.
Syntis Bio aims to provide a more appealing option through a drug that redirects nutrient absorption from the beginning to the end of the small intestine, which helps individuals feel fuller with less food intake—similar to the effects of gastric bypass.
The drug employs two primary ingredients: dopamine and a small amount of hydrogen peroxide.
When these substances interact with an enzyme in the intestine, they form a biocompatible polymer that coats the intestinal lining, designed to last about 24 hours.
This innovative mechanism was developed from research at MIT by Giovanni Traverso and Robert Langer.
Early studies in rats showed consistent weight loss, while a pilot study involving nine human participants reported no adverse effects.
Tissue samples confirmed the temporary polymer coating’s formation and clearance, with subsequent blood tests indicating lowered glucose and hunger hormone levels.
Experts believe this new approach could play a significant role in the future of obesity treatment, potentially serving as a first-line medication to complement existing weight loss options while preserving lean muscle mass.
[READ MORE: Scientists Bring Prehistoric ‘Dire Wolf’ Back From Extinction]
